Presence of Breast Cancer Information Recorded in United Kingdom Primary Care Databases: Comparison of CPRD Aurum and CPRD GOLD (Companion Paper 1)

IF 3.4 2区医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Clinical Epidemiology Pub Date : 2023-12-16 DOI:10.2147/clep.s434795

Katrina Wilcox Hagberg, Catherine Vasilakis-Scaramozza, Rebecca Persson, David Neasham, George Kafatos, Susan Jick

{"title":"Presence of Breast Cancer Information Recorded in United Kingdom Primary Care Databases: Comparison of CPRD Aurum and CPRD GOLD (Companion Paper 1)","authors":"Katrina Wilcox Hagberg, Catherine Vasilakis-Scaramozza, Rebecca Persson, David Neasham, George Kafatos, Susan Jick","doi":"10.2147/clep.s434795","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the presence of data elements related to diagnosis and treatment of malignant breast cancer in CPRD Aurum compared to those in the previously validated CPRD GOLD. Methods: Females in CPRD Aurum or GOLD with a first-time code for malignant breast cancer, mastectomy, or ≥ 1 prescription for tamoxifen or aromatase inhibitors (2004– 2019) were selected. We compared the presence of the codes for breast cancer diagnosis, surgeries (mastectomy, lumpectomy), tamoxifen and aromatase inhibitor prescriptions, radiation, chemotherapy, and supporting clinical codes (suspected breast cancer, lump symptoms, biopsy, lumpectomy, cancer care, referral/visit to specialist, palliative care). Age standardized incidence rates of breast cancer diagnosis in CPRD Aurum and GOLD were calculated. Results: There were 131,936 eligible patients in CPRD Aurum and 69,102 patients in GOLD. A similar proportion of patients in CPRD Aurum and GOLD had codes for breast cancer diagnosis, mastectomy, drug prescriptions, lump, biopsy, lumpectomy, chemotherapy, and cancer and palliative care coded in their electronic record during follow-up. However, suspected breast cancer, radiation, and referral/visits to specialists were coded more frequently in patients in CPRD Aurum compared to GOLD. Age-standardized incidence rates were similar for CPRD Aurum and GOLD. Conclusion: Overall, there was consistency between data elements related to malignant breast cancer recorded in CPRD Aurum and GOLD, particularly for the most informative clinical details. These findings provide reassurance that breast cancer information recorded in CPRD Aurum is generally comparable to that recorded in the previously validated CPRD GOLD and support the use of CPRD Aurum for breast cancer research. Keywords: clinical practice research datalink, CPRD Aurum, CPRD GOLD, breast cancer, validation, data quality","PeriodicalId":10362,"journal":{"name":"Clinical Epidemiology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2023-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Epidemiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/clep.s434795","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the presence of data elements related to diagnosis and treatment of malignant breast cancer in CPRD Aurum compared to those in the previously validated CPRD GOLD.
Methods: Females in CPRD Aurum or GOLD with a first-time code for malignant breast cancer, mastectomy, or ≥ 1 prescription for tamoxifen or aromatase inhibitors (2004– 2019) were selected. We compared the presence of the codes for breast cancer diagnosis, surgeries (mastectomy, lumpectomy), tamoxifen and aromatase inhibitor prescriptions, radiation, chemotherapy, and supporting clinical codes (suspected breast cancer, lump symptoms, biopsy, lumpectomy, cancer care, referral/visit to specialist, palliative care). Age standardized incidence rates of breast cancer diagnosis in CPRD Aurum and GOLD were calculated.
Results: There were 131,936 eligible patients in CPRD Aurum and 69,102 patients in GOLD. A similar proportion of patients in CPRD Aurum and GOLD had codes for breast cancer diagnosis, mastectomy, drug prescriptions, lump, biopsy, lumpectomy, chemotherapy, and cancer and palliative care coded in their electronic record during follow-up. However, suspected breast cancer, radiation, and referral/visits to specialists were coded more frequently in patients in CPRD Aurum compared to GOLD. Age-standardized incidence rates were similar for CPRD Aurum and GOLD.
Conclusion: Overall, there was consistency between data elements related to malignant breast cancer recorded in CPRD Aurum and GOLD, particularly for the most informative clinical details. These findings provide reassurance that breast cancer information recorded in CPRD Aurum is generally comparable to that recorded in the previously validated CPRD GOLD and support the use of CPRD Aurum for breast cancer research.

Keywords: clinical practice research datalink, CPRD Aurum, CPRD GOLD, breast cancer, validation, data quality

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

英国初级医疗数据库中记录的乳腺癌信息：CPRD Aurum 与 CPRD GOLD 的比较（配套文件 1）

目的：评估 CPRD Aurum 与之前经过验证的 CPRD GOLD 中与恶性乳腺癌诊断和治疗相关的数据元素的存在情况：选取 CPRD Aurum 或 GOLD 中首次编码为恶性乳腺癌、乳房切除术或他莫昔芬或芳香化酶抑制剂处方≥1 次（2004-2019 年）的女性。我们比较了乳腺癌诊断、手术（乳房切除术、肿块切除术）、他莫昔芬和芳香化酶抑制剂处方、放疗、化疗以及辅助临床代码（疑似乳腺癌、肿块症状、活检、肿块切除术、癌症护理、转诊/专科就诊、姑息治疗）的存在情况。计算了 CPRD Aurum 和 GOLD 中乳腺癌诊断的年龄标准化发病率：在 CPRD Aurum 中有 131,936 名符合条件的患者，在 GOLD 中有 69,102 名符合条件的患者。在 CPRD Aurum 和 GOLD 中，有相似比例的患者在随访期间的电子记录中记录了乳腺癌诊断、乳房切除术、药物处方、肿块、活检、肿块切除术、化疗以及癌症和姑息治疗的代码。然而，与 GOLD 相比，CPRD Aurum 中患者的疑似乳腺癌、放射治疗和转诊/专科就诊的编码频率更高。CPRD Aurum 和 GOLD 的年龄标准化发病率相似：总体而言，CPRD Aurum 和 GOLD 中记录的恶性乳腺癌相关数据元素是一致的，尤其是在信息量最大的临床细节方面。这些研究结果再次证明，CPRD Aurum 记录的乳腺癌信息与之前经过验证的 CPRD GOLD 记录的乳腺癌信息基本相当，并支持将 CPRD Aurum 用于乳腺癌研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Epidemiology Medicine-Epidemiology

CiteScore

6.30

自引率

5.10%

发文量

169

审稿时长

16 weeks

期刊介绍： Clinical Epidemiology is an international, peer reviewed, open access journal. Clinical Epidemiology focuses on the application of epidemiological principles and questions relating to patients and clinical care in terms of prevention, diagnosis, prognosis, and treatment. Clinical Epidemiology welcomes papers covering these topics in form of original research and systematic reviews. Clinical Epidemiology has a special interest in international electronic medical patient records and other routine health care data, especially as applied to safety of medical interventions, clinical utility of diagnostic procedures, understanding short- and long-term clinical course of diseases, clinical epidemiological and biostatistical methods, and systematic reviews. When considering submission of a paper utilizing publicly-available data, authors should ensure that such studies add significantly to the body of knowledge and that they use appropriate validated methods for identifying health outcomes. The journal has launched special series describing existing data sources for clinical epidemiology, international health care systems and validation studies of algorithms based on databases and registries.